DHAP (chemotherapy)
Jump to navigation
Jump to search
 | This article relies largely or entirely on a single source. (May 2021) |
| DHAP | |
|---|---|
| Specialty | oncology |
DHAP in context of chemotherapy is an acronym for chemotherapy regimen that is used for remission induction in cases of relapsed or refractory non-Hodgkin lymphoma and Hodgkin's lymphoma.[1] It is usually given for 2-3 courses, then followed by high-dose chemotherapy and autologous stem cell transplantation. In combination with anti-CD20 monoclonal antibody rituximab (Rituxan, Mabthera) it is called R-DHAP or DHAP-R.
[R]-DHAP regimen consists of:
- Rituximab, a monoclonal antibody, directed at B-cell surface antigen CD20
- (D)examethasone, a glucocorticoid hormone
- (H)igh-dose (A)ra-C - cytarabine, an antimetabolite;
- (P)latinol (cisplatin), a platinum-based antineoplastic, also an alkylating antineoplastic agent.
Dosing regimen
| Drug | Dose | Mode | Days |
|---|---|---|---|
| (R)ituximab | 375 mg/m2 | IV infusion | Day 0 |
| (D)examethasone | 40 mg | PO qd | Days 1-4 |
| (H)igh-dose Ara-C - cytarabine | 2000 mg/m2 | IV infusion over 2 hrs | Day 2, every 12 hours |
| (P)latinol (cisplatin) | 100 mg/m2 | IV infusion over 24 hrs | Day 1 |